Observational studyEuropean heart journal. Cardiovascular pharmacotherapy2026
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study.
Observational study in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsLarge-scale real-world evidence regarding outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) initiation added to sacubitril-valsartan is currently limited. We aim to investigate effectiveness and safety of SGLT2i initiation among older sacubitril-valsartan users with heart failure in routine clinical practice. METHODS AND
resultsThis prevalent new-user cohort study used linkable administrative data in Ontario, Canada, to emulate a target trial. In sacubitril-valsartan users with heart failure aged ≥66 years, SGLT2i initiators were matched on time-conditional propensity scores to non-initiators (October 2019 to June 2024). The primary effectiveness outcome was a composite of hospitalization for heart failure (HHF) or all-cause mortality. We also studied safety outcomes, including acute kidney injury (AKI), genital infection, urinary tract infection (UTI), falls, hospitalization for hypotension, diabetic ketoacidosis, and hypoglycaemia. Among 5000 matched pairs, SGLT2i initiation was associated with lower HHF or all-cause mortality [hazard ratio (HR) 0.71, 95% confidence interval 0.64-0.78; 1-year absolute risk: 13.9% vs. 19.2%]. Sodium-glucose cotransporter-2 inhibitor initiation was associated with a higher genital infection risk (2.36, 1.58-3.51; 1.8% vs. 0.7%) but not with higher rates of falls, hospitalization for hypotension, or UTI. Diabetic ketoacidosis was uncommon among SGLT2i users with diabetes as were hypoglycaemic events among SGLT2i users without diabetes. Sodium-glucose cotransporter-2 inhibitor initiation showed lower AKI among those with diabetes (0.78, 0.66-0.94) but not among those without diabetes (1.01, 0.66-0.94; HR homogeneity: P = 0.035).
conclusionThis observational real-world evidence study supports effectiveness of SGLT2i among older sacubitril-valsartan users with heart failure, and suggests no increase in the safety outcomes studied, except genital infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.